Published in BMC Med Res Methodol on April 22, 2003
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
The development and description of the comparison group in the Look AHEAD trial. Clin Trials (2011) 1.46
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
Ability of a meta-analysis to prevent redundant research: systematic review of studies on pain from propofol injection. BMJ (2014) 1.05
Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One (2013) 1.03
Comparator bias: why comparisons must address genuine uncertainties. J R Soc Med (2013) 0.99
Uncertainty and equipoise: at interplay between epistemology, decision making and ethics. Am J Med Sci (2011) 0.95
Effectiveness of a hand-held fan for breathlessness: a randomised phase II trial. BMC Palliat Care (2010) 0.84
Controversial choice of a control intervention in a trial of ventilator therapy in ARDS: standard of care arguments in a randomised controlled trial. J Med Ethics (2005) 0.82
When are clinical trials beneficial for study patients and future patients? A factorial vignette-based survey of institutional review board members. BMJ Open (2016) 0.75
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med (2000) 48.03
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet (2001) 31.74
Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med (1992) 17.33
Equipoise and the ethics of clinical research. N Engl J Med (1987) 17.24
What makes clinical research ethical? JAMA (2000) 14.34
Meta-analysis of acute lung injury and acute respiratory distress syndrome trials testing low tidal volumes. Am J Respir Crit Care Med (2002) 10.52
The uncertainty principle and industry-sponsored research. Lancet (2000) 7.75
How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med (1989) 3.84
For and against: clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. BMJ (2000) 3.55
Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. J Clin Epidemiol (1995) 2.74
At what level of collective equipoise does a clinical trial become ethical? J Med Ethics (1991) 2.66
Monitoring of large randomised clinical trials: a new approach with Bayesian methods. Lancet (2001) 2.35
The ethical analysis of risk. J Law Med Ethics (2000) 2.22
Research ethics committees and public dissemination of clinical trial results. Lancet (2002) 2.20
Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. Curr Oncol Rep (2001) 2.09
Is clinical research still too haphazard? Lancet (2001) 1.51
Formal measurement of clinical uncertainty: prelude to a trial in perinatal medicine. The Fetal Compromise Group. BMJ (1994) 1.44
Quantifying and documenting prior beliefs in clinical trials. Stat Med (2001) 1.39
Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol (R Coll Radiol) (1997) 1.38
Meta-analysis of acute lung injury and acute respiratory distress syndrome trials. Am J Respir Crit Care Med (2002) 1.15
Statistics and ethics in surgery and anesthesia. Science (1977) 1.06
The rational use of therapeutic drugs in the 21st century. Important lessons from cumulative meta-analyses of randomized control trials. Int J Technol Assess Health Care (1995) 1.01
Diagnosis and therapy of acute respiratory distress syndrome in adults: an international survey. J Crit Care (1996) 0.97
Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer (2002) 0.96
Clinical trials: two neglected ethical issues. J Med Ethics (1993) 0.95
Ethical issues in the reporting of clinical trials. JAMA (2001) 0.79
Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (2003) 18.72
Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol (2005) 10.99
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 6.92
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med (2012) 5.77
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med (2013) 4.20
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol (2007) 3.85
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst (2006) 3.23
Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med (2014) 2.63
Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst (2009) 2.46
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clin Trials (2010) 2.24
When to perform hepatic resection for intermediate-stage hepatocellular carcinoma. Hepatology (2015) 2.15
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol (2002) 2.01
Randomized trials in oncology stopped early for benefit. J Clin Oncol (2008) 1.89
Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol (2007) 1.86
Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol (2003) 1.71
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med (2002) 1.69
When is diagnostic testing inappropriate or irrational? Acceptable regret approach. Med Decis Making (2008) 1.62
Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.53
Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review. Biol Blood Marrow Transplant (2009) 1.51
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol (2009) 1.46
High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant (2007) 1.45
NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw (2009) 1.44
Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clin Trials (2011) 1.43
Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from U.S. Cooperative Oncology Groups. Clin Cancer Res (2011) 1.42
Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence. Cancer Treat Rev (2006) 1.40
Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials. Contemp Clin Trials (2012) 1.40
Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biol Blood Marrow Transplant (2009) 1.40
Lifting the fog of uncertainty from the practice of medicine. BMJ (2004) 1.35
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med (2007) 1.34
Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med (2012) 1.34
Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol (2012) 1.32
Multiple myeloma. J Natl Compr Canc Netw (2011) 1.28
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev (2009) 1.26
A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol (2007) 1.25
A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making. BMC Med Inform Decis Mak (2010) 1.23
Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev (2012) 1.16
Adherence to antiretroviral therapy in India: a systematic review and meta-analysis. Indian J Community Med (2013) 1.16
Multiple myeloma, version 1.2013. J Natl Compr Canc Netw (2013) 1.14
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2012) 1.10
Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2009) 1.09
Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol (2003) 1.08
Quality and methods of developing practice guidelines. BMC Health Serv Res (2002) 1.06
Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev (2013) 1.03
Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol (2011) 1.01
Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol (2005) 0.99
Comparator bias: why comparisons must address genuine uncertainties. J R Soc Med (2013) 0.99
Systematic review of piperacillin-induced neutropenia. Drug Saf (2007) 0.97
Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control (2007) 0.96
The sound and the fury: financial conflicts of interest in oncology. J Clin Oncol (2007) 0.96
Erythropoietin, uncertainty principle and cancer related anaemia. BMC Cancer (2002) 0.96
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res (2009) 0.96
Extensions to regret-based decision curve analysis: an application to hospice referral for terminal patients. BMC Med Inform Decis Mak (2011) 0.95
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol (2013) 0.95
Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev (2011) 0.94
The Australian 'FORM' approach to guideline development: the quest for the perfect system. BMC Med Res Methodol (2011) 0.93
Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. Br J Haematol (2013) 0.93
Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy (2013) 0.92
Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol (2008) 0.91
Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2). Trials (2009) 0.89
Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (2010) 0.89
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw (2012) 0.89
Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev (2014) 0.88
A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest. Cancer Control (2003) 0.88
High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica (2003) 0.87
Oncology treatment recommendations can be supported only by 1-2% of high-quality published evidence. Cancer Treat Rev (2005) 0.86
Association between competing interests and conclusions. Denominator problem needs to be addressed. BMJ (2002) 0.85
Implications of the principle of question propagation for comparative-effectiveness and "data mining" research. JAMA (2011) 0.84
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2008) 0.84
Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis. Cancer Treat Rev (2012) 0.83
The challenge of systematic reviews of diagnostic and staging studies in cancer. Cancer Treat Rev (2005) 0.81
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. Cochrane Database Syst Rev (2014) 0.81
Optimal type I and type II error pairs when the available sample size is fixed. J Clin Epidemiol (2013) 0.81
Myeloma (multiple). Clin Evid (2006) 0.81
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica (2009) 0.80
Treatment of patients with multiple myeloma: an overview of systematic reviews. Acta Haematol (2010) 0.80
What does randomisation achieve? Evid Based Med (2011) 0.79
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev (2016) 0.79
Failure of equipoise to resolve the ethical tension in a randomized clinical trial. J Law Med Ethics (2003) 0.79
Value of repeat head computed tomography after traumatic brain injury: systematic review and meta-analysis. J Neurotrauma (2013) 0.79
JAMA published fewer industry-funded studies after introducing a requirement for independent statistical analysis. PLoS One (2010) 0.79
Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. Ann Surg (2014) 0.79
Misconceptions, challenges, uncertainty, and progress in guideline recommendations. Semin Hematol (2008) 0.79
Cancer- and treatment-related anemia. J Natl Compr Canc Netw (2005) 0.79
A flexible alternative to the Cox proportional hazards model for assessing the prognostic accuracy of hospice patient survival. PLoS One (2012) 0.78
Identifying homogenous subgroups for individual patient meta-analysis based on Rough Set Theory. Conf Proc IEEE Eng Med Biol Soc (2014) 0.78